IZUMO4: A Potential Drug Target for Various Diseases (G113177)

Target Name: IZUMO4

NCBI ID: G113177

IZUMO4

IZUMO4: A Potential Drug Target for Various Diseases

IZUMO4 (C19orf36) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is a member of the IZUMO gene family, which encodes for a group of proteins that play a role in the regulation of cell growth, differentiation, and survival. One of the functions of these proteins is to promote the expression of genes that are involved in cell proliferation and survival, and to inhibit the expression of genes that are involved in cell death.

Recent studies have identified IZUMO4 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because IZUMO4 has been shown to play a role in the regulation of cell growth and survival, and may be involved in the development and progression of these diseases.

One of the potential mechanisms by which IZUMO4 may be involved in cancer is its role in the regulation of cell proliferation. In many cancers, cells are able to continue to divide and proliferate uncontrollably, leading to the development of tumors. IZUMO4 has been shown to promote the expression of genes that are involved in cell proliferation and survival, which may contribute to the development and progression of cancer.

Another potential mechanism by which IZUMO4 may be involved in neurodegenerative diseases is its role in the regulation of cell death. In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, cells are able to continue to divide and survive for an extended period of time, leading to the development of neurodegeneration. IZUMO4 has been shown to promote the expression of genes that are involved in cell death, which may contribute to the development and progression of these diseases.

IZUMO4 may also be involved in autoimmune disorders, as it has been shown to play a role in the regulation of immune cell function. In autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, the immune system becomes aberrant and attacks the body's own tissues, leading to inflammation and damage. IZUMO4 has been shown to promote the expression of genes that are involved in the regulation of immune cell function, which may contribute to the development and progression of these disorders.

In addition to its potential role in cancer, neurodegenerative diseases, and autoimmune disorders, IZUMO4 may also be involved in other processes in the body. For example, it has been shown to play a role in the regulation of cell migration and the development of tissues, such as the liver and heart. It may also be involved in the regulation of cell signaling pathways, such as the TGF-β pathway, which is involved in cell growth and differentiation.

Overall, IZUMO4 is a protein that has been identified as a potential drug target for a variety of diseases. Its role in the regulation of cell growth, survival, and immune cell function makes it a promising target for the development of new treatments for these diseases. Further research is needed to fully understand the role of IZUMO4 in these processes and to develop effective treatments.

Protein Name: IZUMO Family Member 4

The "IZUMO4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IZUMO4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets